登录

Insight Lifetech Completes ¥200M Series B+ Round, To Launch the First FFR Tool in Direct Measurement

作者: Mailman 2020-04-15 18:07
北芯生命科技
http://www.insight-med.com/
企业数据由 动脉橙 提供支持
心血管介入及植入器械生产商 | D+轮 | 运营中
中国-广东
2022-09-29
夏尔巴投资
查看

According to VCBeat, Shenzhen-based Insight Lifetech Co., Ltd. ("Insight Lifetech") has announced the completion of a ¥200 million Series B+ round of financing. The latest round is led by SDIC Unity Capital, with participation from Green Pine Capital, Efung Capital, TusPark Ventures, and the existing investors Sequoia Capital China and Sherpa Venture Capital.


Proceeds from this financing will be used for the R&D and upgrading of the technology platform, and the launch and sale of Insight Lifetech's first product.


Insight Lifetech is committed to providing high-quality medical devices featuring reliable precision diagnosis and therapy through constantly innovative technologies. The company aims to become a global leading designer and manufacturer in interventional diagnosis and therapy.


Insight Lifetech currently encompasses an office and engineering R&D area of 12000 square feet, and a GMP facility, including ISO Class 7 clean rooms, of about another 12000 square feet. The facility is designed and constructed based upon the latest Good Manufacturing Practice (GMP) requirements by CFDA.


The fractional flow reserve (FFR) measurement system consists of two parts, TruePhysio® pressure microcatheter and VivoCardio® FFR equipment. The TruePhysio® pressure microcatheter is the first MEMS sensor-based rapid exchange FFR system with great performance such as stable and accurate measurement, extremely fine pipe body, significantly low drift rate, and rapid-exchange design.


>>>>

About SDIC Unity Capital


SDIC Unity Capital is a professional guidance fund and parent fund management platform of SDIC Group. It focuses on equity investment in forward-looking and strategic emerging industries and management of parent funds and government-guided funds.


>>>>

About Green Pine Capital


Founded in 2007, Green Pine Capital is one of the most time-honored venture capital institutions in China, with rich experience in biomedicine, new energy and materials, advanced manufacturing, artificial intelligence, and other fields. The company not only provides funds for the invested enterprises, but also provides high-quality post-investment services and integrated resources. Green Pine Capital manages funds of ten billion yuan and has invested more than 7 billion yuan.

相关赛道 心血管耗材
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

Medical Devices Company OptoMedic Completes ¥100 million Series C Financing

Hongyu Medical Closes on ¥30M Series A Round, Providing Interventional Treatment of Heart Disease in Pet Dogs

Medical Device Company Leisheng Medical Completes ¥10M Series A Financing

Coronary Medical Devices Company HS Medical Raises ¥40M in Series Pre-A Round

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Ribo Closes ¥470M Series C2 Funding Round

2020-04-15
下一篇

【生物医药日报】贝瑞基因2019营收同比增长12.35%;汉霖制药利妥昔单抗注射液获药品补充申请批件

2020-04-15